Mar 04, 2021 09:12 JST

Source: Eisai

Eisai to Support Construction of Screening Framework for the Novel Coronavirus Infection in Kenya

TOKYO, Mar 04, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has decided to assent to and support a project led by CA Medlynks Kenya, Ltd., a subsidiary of the healthcare startup company engaged in improving healthcare access in Africa, Connect Afya Co., Ltd., which aims to build a new structure for the efficient testing framework for the novel coronavirus infection in Kenya. CA Medlynks Kenya, Ltd., in collaboration with the government of Meru County in Kenya, will support the setup of PCR testing laboratories, along with procurement of equipment necessary for testing and training of screening technicians.

Meru County, one of Kenya's 47 counties, is the most populous county in the Eastern Province of Kenya with approximately 1.35 million people. As the novel coronavirus infection spreads in Kenya, one issue in Meru County is the time required to receive screening results as samples must be sent across over 200 kilometers to the capital city of Nairobi for testing, a situation which is caused by a lack of equipment, facilities and technicians necessary for screening of the novel coronavirus. It is expected that support for this effort will contribute largely to the formation of accurate and rapid understanding of the infection situation as well as strategy that is based on that understanding by construction of PCR testing in Meru County.

Eisai has committed the equivalent of 1 million USD in aid over the span of 1 year in order to support the controlling of the spread of the novel coronavirus infection in Africa, along with prevention of delays of elimination activities for neglected tropical diseases (NTDs). As part of this support, Eisai has begun provision of Personal Protection Equipment (masks, goggles, face shields, etc.) to core hospitals in Africa for research of and countermeasures against infectious diseases, as well as masks and sanitizer for the resuming of mass drug administrations in Kenya for the elimination of NTDs. In addition, Eisai is supporting Amref Health Africa in the development and popularization of its mobile health platform LEAP for healthcare workers in sub-Saharan countries.

Through this support, including the new support for Connect Afya, Eisai will continue in its contribution to mitigating the spread of the novel coronavirus infection in Kenya and other African countries.

About Connect Afya Co., Ltd. and CA Medlynks Kenya, Ltd.

Connect Afya Co., Ltd. (Headquarters: Hyogo, Japan, CEO: Yoichi Shimada) and its local affiliate CA Medlynks Kenya Ltd. (Location: Nairobi are startups delivering clinical laboratory services and providing in-vitro diagnostic medical equipment, for the realization of a society where people enjoy better lives without suffering from limitations of insufficient medical infrastructure.

As of February 2021, the startup has supplied diagnostic services and in-vitro diagnostic medical equipment, including novel coronavirus infection reverse transcription PCR screening equipment, to over thirty healthcare organizations, clinics, and corporations across Kenya.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 21 2026 23:23 JST
 
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21 2026 19:52 JST
 
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
 
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
 
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
 
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
 
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
 
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
 
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
 
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
 
More Press release >>

Latest Press Release


More Latest Release >>